Last updated: February 15, 2026
What is NDC 57896-0714?
NDC 57896-0714 corresponds to Rimegepant, marketed as Nurtec ODT. It is a prescription medication approved by the FDA in 2020 for acute treatment of migraines and preventive therapy.
Market Overview
- Indication: Treatment of episodic and chronic migraines in adults.
- Marketing approval: FDA approval obtained in February 2020.
- Competition: Several CGRP receptor antagonists and triptans dominate the migraine treatment market.
- Market size: The global migraine drug market was valued at approximately $4.2 billion in 2021 and is projected to reach $6.5 billion by 2026, growing at a CAGR of around 9.2% [1].
Market Penetration
- Initial uptake: Nurtec ODT gained moderate market share after launch, competing with established triptans and newer CGRP inhibitors like erenumab (Aimovig) and fremanezumab (Ajovy).
- Prescriptions: Estimated to have generated approximately 2 million prescriptions globally in 2022.
- Patient adoption: Primarily prescribed for patients seeking rapid relief and convenience due to the oral dissolving tablet form.
Pricing Structure
- US average wholesale price (AWP): Approximately $60 per tablet for Nurtec ODT.
- Insurance coverage: Rebates and tiered insurance plans impact actual patient out-of-pocket costs, which average $20-$30 per dose.
- Dosing: Up to 8 tablets per month for acute treatment; preventive indication may involve higher cumulative costs.
Competitive Landscape
| Drug |
Class |
Approval Year |
Market Share (2022) |
Wholesale Price (approx.) |
| Nurtec ODT |
CGRP receptor antagonist |
2020 |
8% |
$60 per tablet |
| Aimovig |
CGRP monoclonal antibody |
2018 |
12% |
$575 per month (injectable) |
| Ubrogepant (Ubrelvy) |
CGRP receptor antagonist |
2019 |
4% |
$70 per tablet |
| Triptans (sumatriptan, etc.) |
Serotonin agonists |
- |
25% |
$10-$30 per dose |
Note: prices vary by distributor, insurance, and pharmacy.
Price Projection (Next 3-5 Years)
-
Market Penetration Trends:
- Expected increase in prescriptions driven by greater awareness and expanded indications.
- Projected to reach approximately 4 million global prescriptions by 2025.
-
Pricing Trends:
- U.S. prices are unlikely to decline significantly due to limited biosimilar or generic competition.
- Price stabilization anticipated given the drug’s patent exclusivity until at least 2030, with potential for slight reductions driven by formulary negotiations.
-
Generics and Biosimilar Competition:
- No generic versions available currently due to patent protections.
- NDC price pressure may increase with broader adoption of biosimilars or similar agents, although this remains uncertain until patent expiration.
-
Regulatory and Policy Impact:
- Payor negotiations could lower costs marginally.
- Value-based pricing models could influence future drug prices, especially with expanded indications.
Key Financial Projections Summary
| Year |
Estimated Annual Prescriptions |
Projected Wholesale Revenue |
Price per Tablet |
Remarks |
| 2023 |
2.5 million |
~$150 million |
$60 |
Growing prescriptions, stable price |
| 2024 |
3 million |
~$180 million |
$60 |
Slight increase in prescriptions |
| 2025 |
4 million |
~$240 million |
$60 |
Market saturation begins |
Long-term projections assume no significant patent challenges, and prices remain stable.
Strategic Considerations for Investors and R&D
- Market Growth: The expansion of migraine treatment options presents opportunities, but market share of Nurtec ODT depends on physician preference, formulary positioning, and pricing strategies.
- Pricing Power: Limited competition sustains current high price points, though payor pressures could moderate margins.
- Pipeline Development: Potential pipeline drugs targeting similar pathways could erode market share or improve efficacy, impacting future price stability.
Key Takeaways
- Nurtec ODT maintains a strong position due to its quick-dissolving format and dual indication for acute and preventive therapy.
- Market growth is driven by increasing migraine prevalence and patient preferences for oral medications.
- The drug’s price remains stable at approximately $60 per tablet, with no broad generic competition expected until at least 2030.
- Prescriptions are projected to grow 2- to 3-fold over five years, supporting steady revenue expansion.
- Competitive dynamics may influence pricing and market share, especially with new entrants and policy changes.
FAQs
1. What factors influence Nurtec ODT pricing over the next five years?
Pricing stability hinges on patent protection, insurance negotiations, payer policies, and the emergence of competing drugs or generics.
2. How does Nurtec ODT compare to alternatives like Aimovig or Ubrogepant?
Nurtec ODT offers oral administration with rapid onset, while Aimovig is injectable and primarily preventative. Ubrogepant shares similar mechanism but with slightly lower market share and comparable price.
3. What is the impact of patent expiration on Nurtec ODT’s price?
Patent expiration could allow generics, likely reducing prices by 50-70%, but is not expected before 2030.
4. How significant is the role of insurance in Nurtec ODT’s pricing?
Insurance coverage reduces out-of-pocket costs, but formulary restrictions and rebates influence the net pricing and reimbursement rates.
5. What market opportunities exist for new entrants?
Focus areas include developing lower-cost alternatives, expanding indications, or offering longer-lasting formulations to capture market share.
References
- Market Reports, “Global Migraine Market Forecast,” 2021-2026, MarketsandMarkets.
